A detailed history of Bayesian Capital Management, LP transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Bayesian Capital Management, LP holds 13,000 shares of ARWR stock, worth $208,910. This represents 0.03% of its overall portfolio holdings.

Number of Shares
13,000
Holding current value
$208,910
% of portfolio
0.03%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

BUY
$12.74 - $21.53 $165,620 - $279,890
13,000 New
13,000 $165,000
Q1 2024

May 15, 2024

BUY
$27.21 - $39.48 $688,494 - $998,962
25,303 New
25,303 $723,000
Q1 2023

May 15, 2023

BUY
$23.68 - $38.51 $773,909 - $1.26 Million
32,682 New
32,682 $830,000
Q4 2020

Feb 12, 2021

SELL
$43.82 - $85.37 $305,250 - $594,687
-6,966 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$33.21 - $51.27 $231,340 - $357,146
6,966 New
6,966 $300,000
Q2 2020

Aug 14, 2020

SELL
$26.12 - $43.27 $296,044 - $490,422
-11,334 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$20.56 - $63.12 $133,640 - $410,280
6,500 Added 134.46%
11,334 $326,000
Q4 2019

Feb 14, 2020

BUY
$28.14 - $73.01 $136,028 - $352,930
4,834 New
4,834 $307,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $1.7B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.